Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Teal Health, maker of an FDA-approved at-home cervical cancer screening device, just raised $22M in Series A funding to gear up for a 2027 federal mandate requiring most health plans to fully cover self-collected HPV tests. Nearly a quarter of women are overdue for cervical cancer screening, and Teal's at-home model is catching cancer at 5x the expected rate. The company is already in-network with major insurers and bracing for a surge in demand.
Teal Health, the company behind an FDA-approved at-home cervical cancer screening device, has closed a $22 million Series A round led by .406 Ventures, with backing from Emerson Collective, Forerunner, Labcorp, and new Japan-based investor MPower Partners. The raise brings Teal's total funding to $45 million and is aimed squarely at scaling operations ahead of a major policy shift: starting in 2027, most U.S. health plans will be required to cover self-collected HPV tests at no cost to patients.
The timing couldn't be more critical. Nearly a quarter of women are overdue for cervical cancer screening, and a third of women in their 20s have never been screened at all. Teal's model — pairing a self-collection wand with a telehealth visit and results interpretation — is already catching cancer at 5x the rate expected from general population screening, largely because it's re-engaging women who've fallen through the cracks.
By the Numbers:
Why it matters: With a federal coverage mandate on the horizon, at-home cervical cancer screening is poised to shift from a niche convenience to a mainstream preventive care tool — potentially reaching millions of women who've never engaged with traditional screening.
